FastSense
Diagnostics

Our universal diagnostic kit detects diseases early and saves lives.

L-Sense

A market-ready portable device for early screening of cancer. Artificial-Intelligence enabled interface to identify population prone to cancer. Monitoring of treatment regimen and easy follow up of cancer relapse/ metastasis. An easy tool for doctors to quickly analyze patients profile and prediction of disease onset.

PROBLEM

Cancer is the most fatal disease with more than 10 million death each year and the number of new cancer cases may reach close to 25 million a year in the next 2 decades.

According to WHO, the rising burden of cancer places enormous strains on the health-care systems in developing and developed countries. The total annual economic cost of cancer is estimated at approximately US$ 1.16 trillion.

SOLUTION

The major cause of death and expenses related to cancer is the late diagnosis. Even in developed countries, most cases are diagnosed at an advanced stage when no treatment is possible. Diagnosing cancer in late stages, and the inability to provide treatment causes suffering and early death, especially in low to middle-income countries, having less/no access to effective diagnostic services, including imaging, laboratory tests, and pathology.

There is an urgent need to develop cost-effective early diagnosis systems to detect cancer in patients at an earlier stage, enabling treatment that is generally more effective, less complex, and less expensive.

MARKET NEED

1. Portable

2. Affordable

3. Rapid (<1 h)

4. Accurate

5. Easy to operate

6. Minimally invasive

WHAT WE OFFER

A market-ready portable device for early screening of cancer. Artificial-Intelligence enabled interface to identify population prone to cancer. Monitoring of treatment regimen and easy follow up of cancer relapse/ metastasis. An easy tool for doctors to quickly analyze patients profile and prediction of disease onset.

MARKET

The global market on in-vitro diagnosis devices (IVD) has a huge market size and expected to reach $94 Billion in 2025. While in India, the estimated size is more than $700.

Million in 2018 and would expect to reach $1.5-1.7 billion markets by 2020 at a 5-year CAGR 15 – 20%. The main customers for the IVD markets are the stand-alone and chain of Laboratories, Government/ private hospitals, Physicians, pathologists, CROs (as the diagnosis is integral for clinical trials) and Lab heads/Pathologists and NGOs.

Menu